Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05870865 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
A Phase 2 study of Dermatitis, Atopic and Pruritus, sponsored by Formation Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 20
- Study locations
NCT05870865: Completed Phase 2 study of Dermatitis, Atopic and Pruritus, sponsored by Formation Bio.
NCT05870865 is a Phase 2 study of Dermatitis, Atopic and Pruritus that has completed, run by Formation Bio. The registered enrollment target is 144 participants, below the 392-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05870865, a Phase 2 study of Dermatitis, Atopic and Pruritus, has completed, sponsored by Formation Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: * What is the efficacy and safety of ASN008? * What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical ASN008, or matching vehicle (placebo containing no active drug), to their eczema lesions twice daily for 4 weeks. Researchers will compare 3 different doses of ASN008 and a matching vehicle group to see which group responds best.
Primary Outcome
Percent change of 7-day average daily peak pruritus NRS from Baseline to Week 4
Conditions Studied
Interventions
- DRUG ASN008
- OTHER ASN008 Matching Vehicle
Study Locations (20)
California
- TrialSpark Investigative Site 0123 - Beverly Hills
- TrialSpark Investigative Site 0113 - Fremont
- TrialSpark Investigative Site 0101 - Los Angeles
Florida
- TrialSpark Investigative Site 0103 - Miami Lakes
- TrialSpark Investigative Site 0129 - Miramar
Indiana
- TrialSpark Investigative Site 0131 - Clarksville
- TrialSpark Investigative Site 0109 - Indianapolis
Louisiana
- TrialSpark Investigative Site 0108 - Baton Rouge
- TrialSpark Investigative Site 0124 - Monroe
New York
- TrialSpark Investigative Site 0115 - Kew Gardens
- TrialSpark Investigative Site 0119 - New York
Arizona
- TrialSpark Investigative Site 0106 - Scottsdale
Arkansas
- TrialSpark Investigative Site 0118 - Hot Springs
Kentucky
- TrialSpark Investigative Site 0112 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-05-03 |
| Est. Completion | 2023-12-28 |
| Phase | Phase 2 |
What the finished NCT05870865 record still lists
NCT05870865 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 392-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which ASN008 is the first listed.
NCT05870865 names 20 study sites across 14 states, led by California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT05870865 about?
NCT05870865 is a clinical study titled "A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis". The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: * What is the efficacy and safety of ASN008? * What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical A...
What is the current status of trial NCT05870865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2023-05-03. Estimated completion is 2023-12-28.
What conditions does trial NCT05870865 study?
This clinical trial studies the following conditions: Dermatitis, Atopic, Pruritus.
What interventions are being tested in trial NCT05870865?
The interventions under investigation include: ASN008 (DRUG), ASN008 Matching Vehicle (OTHER).
Who is sponsoring clinical trial NCT05870865?
This trial is sponsored by Formation Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05870865 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05870865's enrollment target sits among peer trials
144 21st of 29 higher than 9 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI